Stockscreener 앱 받기
1.37
2.14%
-0.03
시간 외 거래:
1.39
0.02
+1.46%
전일 마감가:
$1.40
열려 있는:
$1.4
하루 거래량:
33,124
Relative Volume:
0.76
시가총액:
$67.43M
수익:
$409.70K
순이익/손실:
$-12.00M
주가수익비율:
-5.6033
EPS:
-0.2445
순현금흐름:
$-9.81M
1주 성능:
-0.72%
1개월 성능:
+0.00%
6개월 성능:
-5.52%
1년 성능:
-2.84%
1일 변동 폭
$1.36
$1.40
1주일 범위
$1.36
$1.45
52주 변동 폭
$1.168
$1.96
Medicinova Inc Stock (MNOV) Company Profile
명칭
Medicinova Inc
전화
858-373-1500
주소
4275 EXECUTIVE SQUARE, LA JOLLA, CA
Compare MNOV vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.37 | 68.91M | 409.70K | -12.00M | -9.81M | -0.2445 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 개시 | H.C. Wainwright | Buy |
| 2021-03-10 | 개시 | Maxim Group | Buy |
| 2019-03-25 | 재개 | B. Riley FBR | Buy |
| 2018-03-28 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-04-18 | 개시 | Credit Suisse | Outperform |
| 2013-01-04 | 재확인 | Ladenburg Thalmann | Buy |
| 2012-05-24 | 다운그레이드 | MLV & Co | Buy → Hold |
| 2011-10-18 | 재확인 | MLV Capital | Buy |
| 2011-06-22 | 개시 | Global Hunter Securities | Buy |
| 2010-05-12 | 개시 | Wedbush | Outperform |
| 2008-11-12 | 재확인 | Ladenburg Thalmann | Buy |
| 2008-05-15 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-07-09 | 개시 | Punk, Ziegel & Co | Buy |
모두보기
Medicinova Inc 주식(MNOV)의 최신 뉴스
MediciNova Completes MN-001-NATG-202 Clinical Trial Evaluating Tipelukast - geneonline.com
MediciNova, Inc. Announces Completion of Last Patient Visit in Phase 2 Trial of MN-001 for Hypertriglyceridemia and NAFLD Associated with Type 2 Diabetes - Quiver Quantitative
Fatty liver, high triglyceride diabetes trial hits final patient visit - Stock Titan
MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast) - GlobeNewswire Inc.
MNOV Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline AdvancesEarnings Cycle Outlook - Newser
MNOV Stock Price, Quote & Chart | MEDICINOVA INC (NASDAQ:MNOV) - ChartMill
MNOV Q1 2026 Earnings: Drug Development Progress Drives Narrower-than-Expected LossHigh Attention Stocks - Newser
MediciNova Inc stock (US58468P2038): biotech eyes IPF and neurology pipeline as investors watch next - AD HOC NEWS
MSN Money - MSN
MediciNova, Inc.Common Stock (NQ: MNOV - FinancialContent
MediciNova stock (US58468P2038): Earnings update after April study news - AD HOC NEWS
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth - Yahoo Finance
MediciNova Inc reports results for the quarter ended March 31Earnings Summary - TradingView
MediciNova: Q1 Earnings Snapshot - KTVB
MediciNova, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
MediciNova (MNOV) Q1 2026 results show lower loss and $27.3M cash - Stock Titan
Medici Nova Biotechnology (MNOV.US) will release its earnings report after the market closes on May 15. - Moomoo
MediciNova Inc stock (US58468P2038): Biopharma innovator targeting unmet needs - AD HOC NEWS
TradingKey - TradingKey
What Medicinova (MNOV) is doing to earn customer loyalty (Tick Down) 2026-05-08Viral Momentum Stocks - newser.com
MediciNova Is Maintained at Buy by D. Boral Capital - Moomoo
D. Boral Capital Reiterates Buy Rating for MediciNova (NASDAQ:MNOV) - MarketBeat
Why are smart money investors paying attention to Medicinova (MNOV)? (Institutional Demand) 2026-05-03Popular Picks - newser.com
MediciNova, Inc. (NASDAQ:MNOV) Sees Large Decrease in Short Interest - MarketBeat
MediciNova Heads to ROTH, Puts Late-Stage Pipeline in Investor Spotlight - BriefGlance
MediciNova (NASDAQ: MNOV) proxy targets 247M authorized shares, board elections - Stock Titan
New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation - Weekly Voice
New Peer‑Reviewed Study Reveals Actionable - GlobeNewswire
D. Boral Capital Maintains MediciNova (MNOV) Buy Recommendation - MSN
Researchers found a brain metastasis weakness — MediciNova plans clinical work - Stock Titan
MediciNova (NASDAQ: MNOV) to vote on 147M share increase, director slate - Stock Titan
Valuation Metrics Overview | Medicinova posts narrower than expected loss, 48.4% EPS beatShared Momentum Picks - Newser
MediciNova (MNOV) asks shareholders to approve 147M share increase ahead of June meeting - Stock Titan
MediciNova, Inc. (NASDAQ:MNOV) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
MediciNova (NASDAQ:MNOV) Share Price Crosses Above Two Hundred Day Moving AverageHere's Why - MarketBeat
What is the bear case for Medicinova (MNOV) Stock | Price at $1.48, Down 1.01%Seasonality Effect - Newser
Gainers Report: What is the next catalyst for MediciNova IncMarket Sentiment Review & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Nasdaq Moves: Whats the MACD signal for MediciNova Inc2026 Spike Watch & Breakout Confirmation Trade Signals - baoquankhu1.vn
Fed Meeting: What is the next catalyst for MediciNova IncRecession Risk & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
MediciNova (NASDAQ:MNOV) Shares Cross Above 200 Day Moving AverageHere's What Happened - MarketBeat
Investor Mood: What analysts say about MediciNova Inc stockSell Signal & Daily Profit Focused Stock Screening - baoquankhu1.vn
Can MediciNova Inc expand its profit marginsQuarterly Growth Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
BYSI PE Ratio & Valuation, Is BYSI Overvalued - Intellectia AI
Sentiment Watch: How sensitive is MediciNova Inc to inflationWeekly Investment Report & Expert Curated Trade Setups - baoquankhu1.vn
Will Medicinova (MNOV) Stock Hit Record Highs | Price at $1.44, Up 1.41%Hull Moving Average - Newser
Buy Signal: What is the next catalyst for MediciNova IncEarnings Risk Summary & Comprehensive Market Scan Insights - baoquankhu1.vn
Winners Losers: Can MediciNova Inc beat the S P 500Forecast Cut & Precise Swing Trade Alerts - baoquankhu1.vn
Medicinova Inc (NASDAQ:MNOV) Reiterates Buy Rating - FXDailyReport.Com
Maxim Group Maintains MediciNova(MNOV.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Maxim Group Reiterates "Buy" Rating for MediciNova (NASDAQ:MNOV) - MarketBeat
MediciNova, Inc. (NASDAQ:MNOV) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Medicinova Inc (MNOV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):